期刊
CURRENT MEDICAL RESEARCH AND OPINION
卷 32, 期 6, 页码 1137-1141出版社
TAYLOR & FRANCIS LTD
DOI: 10.1185/03007995.2016.1162774
关键词
Cancer; Fingolimod; FTY720; PP2A; Therapy
资金
- Instituto de Salud Carlos III FEDER [PT13/0010/0012, PI13/02609, PI15/00934]
FTY720 (Fingolimod, Gilenya(dagger)) is an FDA-approved immunosuppressant currently used in the treatment of multiple sclerosis. However, a large number of studies over the last few years have shown that FTY720 shows potent antitumor properties that suggest its potential usefulness as a novel anticancer agent. Interestingly, the restoration of protein phosphatase 2A (PP2A) activity mediated by FTY720 could play a key role in its antitumor effects. Taking into account that PP2A inactivation is a common event that determines poor outcome in several tumor types, FTY720 could serve as an alternative therapeutic strategy for cancer patients with such alterations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据